Overview

• Overall cancer mortality fell 34% from 1991 to 2023, equating to more than 4.5 million lives saved, with 18.6 million U.S. survivors in 2025.
• From July 2024 through June 2025, the FDA cleared 20 new anticancer drugs, eight new indications, two devices, two minimally invasive colorectal screening tests, and several AI-based detection tools.
• Immunotherapy’s reach expanded sharply, with 56.5% of U.S. patients eligible for checkpoint inhibitors in 2025 versus 1.5% in 2011 and approvals spanning 22 cancer types.
• Rising early-onset trends persisted, including a 5.0% yearly increase in colorectal cancer incidence among people under 50 from 2018 to 2022 and a 1.1% yearly mortality rise for younger adults from 2019 to 2023.
• AACR underscored prevention and equity gaps, noting about 40% of cases stem from modifiable risks and citing a poll showing 83% of voters favor more federal cancer-research funding and 89% support medical research overall.